Immunoinhibitors of factor XIII
AssigneesPresident and Fellows of Harvard College, The General Hospital Corporation
InventorGuy Reed
Life of this patent
Estimating the term…
Abstract
Novel immunoinhibitors are capable of inhibiting thrombin-activated function of Factor XIII by binding to Factor XIII at a site other than the thrombin-cleavage site of Factor XIII.
Claims2
A monoclonal antibody which inhibits the ability of Factor XIII to catalyze the formation of a blood clot, wherein said antibody inhibits thrombin cleavage of said Factor XIII but does not bind to the thrombin-cleavage site of said Factor XIII, wherein said antibody binds to the same epitope on Factor XIII as antibodies selected from the group consisting of 9C11 produced by the hybridoma having the accession number ATCC CRL 11458 and 10G10 produced by the hybridoma having the accession number ATCC CRL 11457.
Dependencies are inferred from the claim text.